LYEL
Lyell Immunopharma Inc
NASDAQ: LYEL · HEALTHCARE · BIOTECHNOLOGY
$19.73
-4.22% today
Updated 2026-04-30
Market cap
$527.78M
P/E ratio
—
P/S ratio
14,660.60x
EPS (TTM)
$-16.06
Dividend yield
—
52W range
$8 – $45
Volume
0.1M
Lyell Immunopharma Inc (LYEL) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $657000.00 | $7.76M | $10.65M | $84.68M | $130000.00 | $61000.00 | $36000.00 |
| Revenue growth (YoY) | — | +1080.5% | +37.3% | +695.1% | -99.8% | -53.1% | -41.0% |
| Cost of revenue | — | $7.47M | $14.54M | $16.47M | $20.25M | — | $11.54M |
| Gross profit | $657000.00 | $7.76M | $10.65M | $84.68M | $130000.00 | $61000.00 | $-11.50M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -31952.8% |
| R&D | $63.59M | $182.24M | $138.69M | $159.19M | $182.94M | $171.60M | $158.68M |
| SG&A | $39.15M | $46.88M | $89.06M | $117.31M | $66.98M | $52.04M | $45.13M |
| Operating income | $-102.09M | $-211.94M | $-214.78M | $-187.06M | $-247.01M | $-358.75M | $-203.77M |
| Operating margin | -15538.7% | -2732.6% | -2016.7% | -220.9% | -190006.2% | -588123.0% | -566038.9% |
| EBITDA | $-100.83M | $-215.43M | $-201.15M | $-169.04M | $-226.76M | $-200.64M | $-192.24M |
| EBITDA margin | -15347.5% | -2777.6% | -1888.8% | -199.6% | -174429.2% | -328923.0% | -533986.1% |
| EBIT | $-102.09M | $-219.72M | $-214.78M | $-187.06M | $-247.01M | $-220.27M | $-203.77M |
| Interest expense | $0.00 | $5.94M | $1.17M | — | — | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-129.38M | $-204.47M | $-250.22M | $-183.12M | $-234.63M | $-342.99M | $-274.45M |
| Net income growth (YoY) | — | -58.0% | -22.4% | +26.8% | -28.1% | -46.2% | +20.0% |
| Profit margin | -19692.1% | -2636.3% | -2349.5% | -216.2% | -180486.2% | -562285.2% | -762355.6% |